File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model

TitleAnti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis model
Authors
Issue Date2007
PublisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtml
Citation
American Journal Of Chinese Medicine, 2007, v. 35 n. 4, p. 663-667 How to Cite?
AbstractIsoflavonoids isolated from plants have been confirmed to fight osteoporosis and promote bone health. However, few studies have been conducted to describe the anti-osteoporosis activity of botanical flavonone. Based on the experimental outcomes, we demonstrated the ability of naringin to fight osteoporosis in vitro. We developed a retinoic acid-induced osteoporosis model of rats to assess whether naringin has similar bioactivity against osteoporosis in vitro. After a 14-day supplement of retinoic acid to induce osteoporosis, SD rats were administered naringin. A blood test showed that naringin-treated rats experienced significantly lower activity of serum alkaline phosphatase and had higher femur bone mineral density, compared to untreated rats. All three dosages of naringin improved the decrease in bone weight coefficient, the length and the diameter of the bone, the content of bone ash, calcium, and phosphorus content induced by retinoic acid. The data of histomorphological metrology of naringin groups showed no difference as compared to normal control rats. These outcomes suggest that naringin offer a potential in the management of osteoporosis in vitro. © 2007 World Scientific Publishing Company Institute for Advanced Research in Asian Science and Medicine.
Persistent Identifierhttp://hdl.handle.net/10722/179441
ISSN
2015 Impact Factor: 2.959
2015 SCImago Journal Rankings: 0.797
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWei, Men_US
dc.contributor.authorYang, Zen_US
dc.contributor.authorLi, Pen_US
dc.contributor.authorZhang, Yen_US
dc.contributor.authorSse, WCen_US
dc.date.accessioned2012-12-19T09:56:37Z-
dc.date.available2012-12-19T09:56:37Z-
dc.date.issued2007en_US
dc.identifier.citationAmerican Journal Of Chinese Medicine, 2007, v. 35 n. 4, p. 663-667en_US
dc.identifier.issn0192-415Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/179441-
dc.description.abstractIsoflavonoids isolated from plants have been confirmed to fight osteoporosis and promote bone health. However, few studies have been conducted to describe the anti-osteoporosis activity of botanical flavonone. Based on the experimental outcomes, we demonstrated the ability of naringin to fight osteoporosis in vitro. We developed a retinoic acid-induced osteoporosis model of rats to assess whether naringin has similar bioactivity against osteoporosis in vitro. After a 14-day supplement of retinoic acid to induce osteoporosis, SD rats were administered naringin. A blood test showed that naringin-treated rats experienced significantly lower activity of serum alkaline phosphatase and had higher femur bone mineral density, compared to untreated rats. All three dosages of naringin improved the decrease in bone weight coefficient, the length and the diameter of the bone, the content of bone ash, calcium, and phosphorus content induced by retinoic acid. The data of histomorphological metrology of naringin groups showed no difference as compared to normal control rats. These outcomes suggest that naringin offer a potential in the management of osteoporosis in vitro. © 2007 World Scientific Publishing Company Institute for Advanced Research in Asian Science and Medicine.en_US
dc.languageengen_US
dc.publisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/ajcm/ajcm.shtmlen_US
dc.relation.ispartofAmerican Journal of Chinese Medicineen_US
dc.subject.meshAlkaline Phosphatase - Blood - Metabolismen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBone Density - Drug Effectsen_US
dc.subject.meshCalcium - Metabolismen_US
dc.subject.meshDisease Models, Animalen_US
dc.subject.meshFemaleen_US
dc.subject.meshFemur - Drug Effects - Metabolismen_US
dc.subject.meshFlavanones - Pharmacology - Therapeutic Useen_US
dc.subject.meshMinerals - Metabolismen_US
dc.subject.meshOsteogenesis - Drug Effectsen_US
dc.subject.meshOsteoporosis - Chemically Induced - Drug Therapy - Prevention & Controlen_US
dc.subject.meshPhosphorus - Metabolismen_US
dc.subject.meshPhytotherapy - Methodsen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Sprague-Dawleyen_US
dc.subject.meshTretinoinen_US
dc.titleAnti-osteoporosis activity of naringin in the retinoic acid-induced osteoporosis modelen_US
dc.typeArticleen_US
dc.identifier.emailZhang, Y: ybzhang@hku.hken_US
dc.identifier.authorityZhang, Y=rp01410en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1142/S0192415X07005156en_US
dc.identifier.pmid17708632-
dc.identifier.scopuseid_2-s2.0-34548174431en_US
dc.identifier.hkuros135880-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34548174431&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume35en_US
dc.identifier.issue4en_US
dc.identifier.spage663en_US
dc.identifier.epage667en_US
dc.identifier.isiWOS:000249451000011-
dc.publisher.placeSingaporeen_US
dc.identifier.scopusauthoridWei, M=55167127000en_US
dc.identifier.scopusauthoridYang, Z=12139011100en_US
dc.identifier.scopusauthoridLi, P=7404772682en_US
dc.identifier.scopusauthoridZhang, Y=23483121900en_US
dc.identifier.scopusauthoridSse, WC=19934749900en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats